In 24 adults with severe uncontrolled asthma who were early responders to dupilumab, this study assessed whether extending the dosing interval beyond the licensed every-2-weeks schedule could maintain disease control, comparing outcomes at baseline (pre-biologic), after standard 2-week dosing (~6.7 months), and after interval prolongation (~8.6 months further).
Extending the median dosing interval to every 4 weeks (range 2–6 weeks) maintained disease control: FEV1% predicted stayed stable (93.5% → 94.2%), FeNO remained suppressed (22.8 → 24.9 ppb), ACQ-6 stayed low (0.7 → 0.5), and annualized exacerbation rate remained 0.0 — all with no statistically significant difference between the standard-dosing and prolonged-dosing visits.
Very small sample size (n=24) with no control group, limiting generalizability; patients were selected as 'early responders,' so findings may not apply to all dupilumab users; no randomization or blinding.
In carefully selected dupilumab early responders with severe asthma, extending the dosing interval to every 4 weeks appears feasible without losing disease control, which could reduce drug costs and injection burden — but larger controlled studies are needed before adopting this routinely.